MUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023 with our tissue engineering therapy
With our novel therapy platform for skeletal muscle regeneration, the MUVON team has won the prize of 10k as a runner up for the ZKB...
MUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023 with our tissue engineering therapy
First in Human trial results published, demonstrating safety and feasibility of MUVON's SUI Therapy
MUVON Therapeutics nominated as finalist for 2023 ZKB Pionierpreis
The leadership from MUVON Therapeutics AG will be attending JP Morgan Healthcare week in Jan 2023
MUVON Therapeutics announces appointments to its Board of Directors and Scientific Advisory Board
Muvon Therapeutics Announces First Patient Enrolled in Phase II Clinical Study
CEO Deana Mohr honored to present MUVON to Prof. Shinya Yamanaka, godfather of iPSCs
Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with SUI
MUVON Therapeutics is supported by the Lichtsteiner Foundation
MUVON's CEO Deana Mohr featured in Top 30 In Vivo's Rising Leaders 2022
CEO Deana Mohr presented MUVON in interview for BioInnovation Spotlight
Translation and automation hurdles for cell therapies
MUVON wins second place at IFAS Innovation Challenge 2021
Deana Mohr wins spot in Venture Leaders Medtech 2021
MUVON featured by Startupticker
MUVON Therapeutics selected as finalist for the 2021 >>venture>> Startup Competition
MUVON Therapeutics selected for Tech4Eva accelerator program
MUVON is being accelerated by Wyss Zurich
The Beginning of the MUVON Story